Pharmacokinetic and immunogenicity analysis Emactuzumab systemic exposure (area under the curve last ) showed a greater than dose-proportional increase from 500 mg to 1000 mg of emactuzumab, accompanied by an overall trend of total clearance decline (range: 346 to 752 mL/day), indicating that the elimination of emactuzumab was predominantly target-mediated following 500 mg and 750 mg q3w dosing in combination with selicrelumab ( online supplemental figure 1 and table 1 ).
← all excerpts
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.
1
—
—